Evidence map›Paper›PMID 41559052›Full record

ArticleNature communications2026

Biochemical principles of miRNA targeting in flies.

Joel Vega-Badillo, Phillip D Zamore, Karina Jouravleva

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Joel Vega-BadilloRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA. joel.vegabadillo@umassmed.edu.ORCID http://orcid.org/0000-0002-7110-6377
Phillip D ZamoreRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0000-0002-4505-9618
Karina JouravlevaLaboratoire de Biologie et Modélisation de la Cellule, École Normale Supérieure de Lyon, CNRS UMR5239, Inserm U1293, Université Claude Bernard Lyon 1, Lyon, France. karina.jouravleva@ens-lyon.fr.ORCID http://orcid.org/0000-0003-2591-3116

Funding

Understanding the Evolution, Biology, and Molecular Mechanism of Argonaute ProteinsR35GM136275 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI PHILLIP D ZAMORE · 2020 to 2026
$3.3M
Howard Hughes Medical Institute (HHMI) noneNIGMS NIH HHS R35 GM136275U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35GM136275
6 · The paper itself

Abstract

MicroRNAs direct Argonaute proteins to repress complementary target mRNAs via mRNA degradation or translational inhibition. While mammalian miRNA targeting has been well studied, the principles by which Drosophila miRNAs bind their target RNAs remain to be fully characterized. Here, we use RNA Bind-n-Seq to systematically identify binding sites and measure their affinities for five highly expressed Drosophila miRNAs. Our results reveal a narrower range of binding site diversity in flies compared to mammals, with fly miRNAs favoring canonical seed-matched sites and exhibiting limited tolerance for imperfections within these sites. We also identified non-canonical site types, including nucleation-bulged and 3'-only sites, whose binding affinities are comparable to canonical sites. These findings establish a foundation for future computational models of Drosophila miRNA targeting, enabling predictions of regulatory outcomes in response to cellular signals, and advancing our understanding of miRNA-mediated regulation in flies.

Indexed as

Drosophila melanogasterMicroRNAsAnimalsArgonaute ProteinsBinding SitesDrosophila ProteinsGene Expression RegulationRNA, MessengerArgonaute ProteinsDrosophila ProteinsMicroRNAsRNA, Messenger

Identifiers

PMID41559052
PMCPMC12905440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.